Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Research and Innovation Action · Running

PREVENTABLE Cancer Prevention vs Cancer Treatment: the Rare Tumour Risk Syndromes Battle

Coordinator
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do Porto, Portugal
Runs
1 January 2023 to 30 June 2026
Status
Running
EU funding
€4.6m
Total cost
€4.7m
Partners
16 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101095483

What the project is doing

In the project's own words, from its summary on CORDIS.

Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS, the lifetime risk to develop various cancers can be as high as 100%, and patients have a 50% chance of transmitting the disease to their offspring. When undiagnosed or not surveilled, many asymptomatic RTRS patients develop particularly aggressive cancers, leading to premature death, severely impacting theirs and their families’ health and wellbeing.

Cancers in RTRS can be prevented and survival rates maximized if asymptomatic RTRS patients are intensively surveilled for RTRS-prone organs, cancer-prone organs are surgically removed prior to disease development, or very small cancerous or pre-cancerous lesions are removed or treated. RTRS are therefore a unique and tangible context for cancer prevention, early diagnosis and treatment with curative intent. However, risk-reduction strategies are not always prioritized in genetically diagnosed and asymptomatic RTRS patients, and most healthcare systems keep on opting for treatment of clinically expressed cancer.

This occurs despite the knowledge that hospitalization has the highest weight on advanced cancer healthcare spending. It is therefore urgent to demonstrate the cost-benefit of the application of preventive measures in RTRS syndromes. The ambition of the PREVENTABLE project is to merge specialized clinical knowledge on RTRS pathways of care, real-life clinical data from RTRS patients and experiences from professionals and patients, with health economic models and social sciences approaches to estimate the cost-benefit of risk-reduction interventions in RTRS and delineate guidelines for its communication among and within clinical teams and RTRS patients.

PREVENTABLE project results will be delivered to a diversity of stakeholders, including policy-makers, in order to promote the implementation of cost-effective RTRS patient-centered care in Europe.

Who is involved

OrganisationCityCountryRole
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalCoordinator
European Health Management AssociationBruxelles / BrusselBelgiumParticipant
Universitatsklinikum BonnBonnGermanyParticipant
Fundacio Institut D'investigacio Biomedica De Girona Doctor Josep TruetaGironaSpainThird party
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainThird party
Institut Catala D'oncologiaHospitalet de LlobregatSpainParticipant
Centre Hospitalier RouenRouenFranceParticipant
Centre Regional De Lutte Contre Le Cancer Henri Becquerel RouenRouenFranceThird party
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
Helse Bergen HfBergenNorwayParticipant
Ipatimup - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto PcupPortoPortugalThird party
Sociedade Portuguesa De Inovacao Consultadoria Empresarial E Fomento Da Inovacao SAPortoPortugalParticipant
Unidade Local De Saude De Sao Joao, E.p.e.PortoPortugalThird party
Universidade Nova De LisboaLisboaPortugalParticipant
Region StockholmStockholmSwedenParticipant
University of LancasterLancasterUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI